(Q46090252)

19 December 2017

title

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia (English)

1 reference

19 December 2017

Erratum: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

main subject

chronic myeloid leukemia

0 references

0 references

1 reference

1 reference

corrigendum / erratum

1 reference

12 July 2019

http://api.crossref.org/works?select=update-to&filter=doi:10.1038/LEU.2010.71

F Guilhot

3

0 references

Andreas Hochhaus

object named as

A Hochhaus

1

0 references

Richard A. Larson

14

object named as

R A Larson

1 reference

19 December 2017

Timothy Hughes

13

object named as

T P Hughes

1 reference

19 December 2017

author name string

S G O'Brien

2

1 reference

19 December 2017

B J Druker

4

1 reference

19 December 2017

S Branford

5

1 reference

19 December 2017

L Foroni

6

1 reference

19 December 2017

J M Goldman

7

1 reference

19 December 2017

M C Müller

8

1 reference

19 December 2017

J P Radich

9

1 reference

19 December 2017

M Rudoltz

10

1 reference

19 December 2017

M Mone

11

1 reference

19 December 2017

I Gathmann

12

1 reference

19 December 2017

IRIS Investigators

15

1 reference

19 December 2017

publication date

12 March 2009

1 reference

19 December 2017

published in

Leukemia

1 reference

19 December 2017

volume

23

1 reference

19 December 2017

issue

6

1 reference

19 December 2017

page(s)

1054-1061

1 reference

19 December 2017

https://scigraph.springernature.com/pub.10.1038/leu.2009.38

exact match

0 references

cites work

Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.38

7 January 2021

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.38

7 January 2021

JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.38

7 January 2021

Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.38

7 January 2021

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.38

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.38

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.38

7 January 2021

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.38

7 January 2021

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.38

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.38

7 January 2021

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.38

7 January 2021

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.38

7 January 2021

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.38

7 January 2021

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.38

7 January 2021

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.38

7 January 2021

BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using str

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.38

7 January 2021

Practical management of patients with chronic myeloid leukemia receiving imatinib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.38

7 January 2021

Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.38

7 January 2021

Congestive heart failure is a rare event in patients receiving imatinib therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.38

7 January 2021

In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.38

7 January 2021

In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.38

7 January 2021

In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.38

7 January 2021

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.38

7 January 2021

Identifiers

DOI

10.1038/LEU.2009.38

1 reference

19 December 2017

Dimensions Publication ID

1002899527

0 references

Fatcat ID

release_ihn2zmbb6fh75b5mji65gcaedm

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ihn2zmbb6fh75b5mji65gcaedm

24 November 2022

mapped directly with Wikidata item

1 reference

19 December 2017